I notice the collaboration includes bi-specific antibodies. There seems to be some skepticism about bi-specific antibodies in the oncology community. Do you view this collaboration as somewhat a validation of the bi-specific antibody technology, in general? Do you think this gives any sort of validation to AFMD's bi-specific antibody technology. (Lindhtu and I seem to be the only ones here interested in AFMD. The stock has seemingly bottomed out.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.